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ABSTRACT
Objectives To evaluate the annual direct medical cost
of managing adult systemic lupus erythematosus (SLE)
patients with active autoantibody positive disease in
Europe.
Methods A 2-year, retrospective, multicentre,
observational study was conducted in five countries
(France, Germany, Italy, Spain and the UK). Data
included patients’ characteristics, disease activity and
severity, flare assessments and health resource use (eg,
laboratory tests, medications, specialist visits and
hospitalisations). Costs were assessed from the public
payers’ perspective. Cost predictors were estimated by
multivariate regression models.
Results Thirty-one centres enrolled 427 consecutive
eligible patients stratified equally by disease severity. At
baseline, mean (SD) age was 44.5 (13.8) years, 90.5%
were women and mean (SD) SLE duration was 10.7
(8.0) years. The SELENA-SLEDAI (11.2 vs 5.3) and
SLICC/ACR index (1.0 vs 0.7) scores were higher in
severe patients. Over the study period, patients
experienced on average 1.02 (0.71) flares/year. The
mean annual direct medical cost was higher in severe
compared to non-severe patients (€4748 vs €2650,
p<0.001). Medication costs were €2518 in severe versus
€1251 in non-severe patients (p<0.001). Medications
represented 53% and 47% of the total cost for severe
and non-severe patients, respectively, primarily due to
immunosuppressants and biologics. Flares, especially
severe flares, were identified as the major cost predictor,
with each flare increasing the annual total cost by about
€1002 (p<0.001).
Conclusions The annual direct medical cost of SLE
patients in Europe is related to disease severity and
flares. Medical treatments were the main cost drivers.
Severe flares and major organ involvement were
identified as important cost predictors.
INTRODUCTION
Systemic lupus erythematosus (SLE) is a multi-
organ, autoimmune disease characterised by alter-
nating periods of disease activity and remission.
Numerous organs may be affected (skin, joints,
lungs, heart, kidneys and brain) leading to a wide
combination of clinical manifestations.1 2
Patients may receive several drug combinations
including corticosteroids, non-steroidal anti-
inflammatory drugs (NSAIDs), antimalarials and
immunosuppressive/cytotoxic drugs.3–5 In recent
years, biological agents, especially rituximab, have
been widely used in Europe as an off-label treat-
ment in patients with refractory disease.6 7
Several studies show that SLE imposes a substan-
tial economic burden on the healthcare system and
on society, due to both direct and indirect costs.8–13
Data on SLE costs are available for Asia, Europe
and North America, but are very limited and/or out-
dated for Europe. A tri-nation study, in the UK,
Canada and the USA,14–16 evaluated the costs of
treating SLE patients over a 4-year follow-up period.
Applying Canadian unit costs, Sutcliffe et al17
reported the costs for 105 patients assessed over a
4-month period in the UK, while Huscher et al11 esti-
mated the costs for 844 patients over 12 months in
Germany.
It has recently been highlighted that little
research has been conducted which examines varia-
tions in costs associated with disease activity, sever-
ity, disease manifestations or with specific
treatments.18
The aim of this study was to evaluate the annual
direct medical cost for adult SLE patients with
active, autoantibody positive disease, and to iden-
tify the cost drivers (eg, medications) and predic-
tors (eg, flares) in five European countries (France,
Germany, Italy, Spain and the UK).
PATIENTS AND METHODS
Study design
The LUpus erythematosus Cost of Illness in Europe
study (LUCIE) is a 2-year multi-centre, retrospect-
ive study based on data reported in patients’
medical records. The study was carried out in
France, Germany, Italy, Spain and the UK, in 26
hospital and five office-based practices (in
Germany, to reflect the national specific manage-
ment of SLE), from October 2010 to April 2011.
In each country between four and 10 centres spe-
cialising in SLE management enrolled between five
and 50 SLE patients with active, autoantibody posi-
tive disease. SLE disease was considered active in
the presence of one of the two following criteria:
(1) one change in treatment related to SLE activity
(increase in dose and/or new treatment) and/or the
occurrence of a new manifestation or worsening of
clinical symptoms of SLE; or (2) one positive bio-
marker of SLE activity (anti-dsDNA antibodies and/
or C3 or C4 below normal) and one clinical and/or
haematological feature of SLE.
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Each country enrolled 50% severe and 50% non-severe
patients. Severe patients were defined as having at least one
major domain involved at inclusion (renal, neurological, cardio-
vascular or respiratory) and requiring prednisone equivalent
dosages >7.5 mg/day and/or immunosuppressants. Patients’
disease activity and severity were assessed at baseline.
Patients who met the inclusion criteria were pre-selected for
inclusion into the study. Patients were screened between January
and June 2008 to identify the inclusion visit where the patient
met the eligibility criteria (figure 1).
The study followed the local legal requirements. It was
approved by the local ethics committees in Germany, Italy and
the UK, where informed consent was obtained from each
patient, and by the national regulatory authorities in France and
Spain.
Disease activity and organ damage assessment
Disease activity and organ damage were evaluated retrospect-
ively at baseline using the SELENA-SLEDAI instrument19 and
the SLICC/ACR index,20 respectively.
Definition, identification and severity of flares
Flare occurrence and its severity were defined by treatment
changes (ie, increasing dose of corticosteroids and/or initiating a
new SLE treatment) and/or hospitalisation, based on an adapta-
tion of the SELENA-SLEDAI flare index.21 It was not possible
to identify the end of a flare. In the event of two consecutive
flares, the second one was considered to be a new flare if it
occurred more than 60 days after the beginning of the first one.
Healthcare resource evaluation and cost calculation
The direct annual medical costs were assessed for each country
from the public payers’ perspective. The units of resource use
were converted in monetary costs using the local official unit cost
databases available in 2011 (see online supplementary table S1).
Information on all resources used (medications, laboratory
tests, biopsies, imaging tests, specialist visits and hospitalisations)
was collected from the medical records for each patient over the
2-year follow-up study period.
Costs were first calculated for each patient. Unit costs were
attributed to each unit of medical resource per category. Then
for each resource category the costs of the overall study sample
were pooled and divided by the corresponding number of
patients. Total direct costs were calculated for each patient over
the follow-up study period and expressed as an annual value
taking into account the individual number of months of
follow-up.
An ancillary study was conducted in nine centres (three per
country) in France, Italy and Spain to evaluate the distribution of
disease severity (severe and non-severe patients) of the overall SLE
population. Results were applied to the study sample to ensure
that the costs were representative of the active SLE population.
Statistical analysis
Statistical analysis was performed using SAS V.9.1 (SAS Institute
Inc, Cary, North Carolina, USA) under the Windows operating
system.
All variables were analysed independently at the country level
and then for the entire study sample. Data were analysed on the
entire sample and also stratified by disease severity (severe vs
non-severe).
The two-sample t test or Mann-Whitney test was used for
quantitative variables and the χ2 test or Fisher’s exact test for
qualitative variables. Statistical significance was set at 0.05.
Cost predictors associated with annual direct medical costs
were identified using multivariate regression models. Annual
direct medical costs (dependent variable) were normalised using
a logarithmic transformation. Univariate regression models were
performed for each independent variable and a p value thresh-
old of 0.1 was applied for selecting variables for inclusion in the
multivariate model and assessing the possible colinearity
between selected independent variables. The backward selection
method was used to determine the best fitting model to predict
annual direct medical costs. In addition, in order to assess and
explain possible differences between countries, the variables
indicating each of the five European countries were included in
the model with the UK serving as the reference country.
RESULTS
A total of 427 eligible patients, consisting of 212 severe (49.6%)
and 215 non-severe (50.4%) patients, were included in the ana-
lysis. Ten patients were excluded because of non-compliance with
eligibility criteria (see online supplementary figure S1). The mean
(SD) follow-up study duration was 24.7 (3.2) months.
Baseline characteristics
Table 1 reports the baseline demographics and clinical character-
istics of patients.
Patients’ mean (SD) age was 44.5 (13.8) years, 90.5% were
women, 84.5% were Caucasian, 10.6% were black, 3.0% were
Central/South Asian and 1.8% were East/South East Asian or
other. (Data on ethnicity were not collected in France because
of ethics considerations.) Mean (SD) SLE duration was 10.7
(8.0) years.
Figure 1 Design of the study.
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Disease activity and organ damage
The mean (SD) SELENA-SLEDAI score was 8.2 (6.7), and twice
as high in severe compared to non-severe patients (p<0.001)
(table 1). The disease was most active in major organs, and in
severe patients. The proportion of major organs involved in
severe patients was 6, 12 and 30 times higher than in non-severe
patients (p<0.001 each) for the renal, cardiovascular/respiratory
and neurological systems, respectively.
The mean (SD) SLICC/ACR index score was 0.8 (1.4) and
was also higher in severe patients (p=0.010). Notably, 50.0%
of severe versus 33.5% of non-severe patients (p<0.011) had at
least one damaged organ. The proportion of major organ
damage in severe patients was 5.3 times higher (p<0.001) for
renal and 2.2 times higher (p<0.01) for neuropsychiatric
systems than in non-severe patients.
Antibodies and complement
ANA, anti-dsDNA, anti-ENA and anti-phospholipid antibodies
were positive, respectively, in 97.1%, 70.8%, 63.5% and 43.6%
of patients. C3 and C4 were below normal in 45.0% and
50.0% of patients. In severe patients, biomarkers related to
disease activity were more frequently impaired: anti-dsDNA
(77.6% vs 63.6%, p<0.01), C3 (53.1% vs 36.6%, p=0.003)
and C4 (57.1% vs 42.7%, p=0.02).
Analysis of flares
Most patients (87.6%) had a flare at least once over the study
period (see online supplementary table S2). Twice as many
severe patients experienced severe flares compared to non-severe
patients (71.2% vs 34.4%, p<0.001).
The mean (SD) annual number of flares was 1.02 (0.71), con-
sisting of 0.54 mild/moderate and 0.47 severe flares. Severe
patients had more frequent flares compared to non-severe
patients (1.13 vs 0.91 flare, p=0.001) and were more likely to
experience severe flares (0.70 vs 0.25 flare, p<0.001).
The mean (SD) annual number of severe flares requiring hos-
pitalisation was 0.25 (0.52), which was also higher in severe
patients (0.36 vs 0.14, p<0.001).
Patients experiencing flares were most commonly treated with
either corticosteroids (94.3%), antimalarials (68.1%) or immu-
nosuppressants (67.5%). Immunosuppressants (81.8% vs
54.9%, p<0.001) and biologics (10.5% vs 1.7%, p<0.001)
were more often prescribed for treating severe flares compared
with mild/moderate flares. Both drugs were frequently used in
combination with corticosteroids (see online supplementary
table S3).
Direct medical cost
The mean annual direct medical cost of treating severe patients was
1.8 times higher than non-severe patients (€4748 vs €2650,
p<0.001; table 2). Avery wide range of costs was observed in both
groups (from €117 to €37 130). The mean (SD) annual direct
medical cost of the study population was €3691 (€4411) which
ranged from €2513 to €4833 in the five countries (figure 2).
Table 2 Mean annual direct medical cost of active SLE patients by
disease severity
Annual direct







Total annual cost (€)





Q1, 25th percentile; Q3, 75th percentile; SLE, systemic lupus erythematosus.












Mean (SD) 40.4 (12.7) 46.3 (14.1) <0.001
Median (min–max) 39.0 (18–82) 45.0 (18–81)
Gender
Females 178 (85.3%) 195 (95.1%) 0.002
Disease duration (years)
Mean (SD) 10.1 (7.6) 11.4 (8.4) 0.109
SELENA-SLEDAI
Score (continuous)
Mean (SD) 11.2 (7.7) 5.3 (3.9) <0.001
Score (categorical)
<10 101 (47.6%) 183 (85.1%) <0.001
≥10 111 (52.4%) 32 (14.9%)
Systems involved
≥1 system 209 (98.6%) 192 (89.3%)
≥3 systems 94 (44.3%) 46 (21.4%) <0.001
Systems with activity*
Immunology 179 (84.4%) 147 (68.4%) <0.001
Musculoskeletal 61 (28.8%) 78 (36.3%) 0.098
Mucocutaneous 63 (29.7%) 75 (34.9%) 0.254
Renal 117 (55.2%) 20 (9.3%) <0.001
Haematological 27 (12.7%) 31 (14.4%) 0.612
CNS 32 (15.1%) 1 (0.5%) <0.001
Constitutional 15 (7.1%) 12 (5.6%) 0.526
Cardiovascular and respiratory 23 (10.8%) 2 (0.9%) <0.001
Vascular 15 (7.1%) 8 (3.7%) 0.125
SLICC/ACR index
Score (continuous)
Mean (SD) 1.0 (1.5) 0.7 (1.2) 0.010
Score (categorical)
<2 158 (74.5%) 182 (84.7%) 0.009
≥2 54 (25.5%) 33 (15.3%)
Systems damaged
≥1 system 106 (50.0%) 72 (33.5%)
≥3 systems 16 (7.5%) 8 (3.7%) 0.011
Systems damaged*
Musculoskeletal system 30 (14.2%) 32 (14.9%) 0.830
Neuropsychiatric system 39 (18.4%) 18 (8.4%) 0.002
Ocular system 18 (8.5%) 16 (7.4%) 0.689
Renal system 26 (12.3%) 5 (2.3%) <0.001
Skin system 16 (7.5%) 13 (6.0%) 0.538
Pulmonary system 13 (6.1%) 6 (2.8%) 0.094
Cardiovascular system 8 (3.8%) 10 (4.7%) 0.652
Peripheral vascular system 10 (4.7%) 7 (3.3%) 0.440
Gastrointestinal system 1 (0.5%) 1 (0.5%) 1.000
Diabetes 5 (2.4%) 3 (1.4%) 0.501
Premature gonadal failure 3 (1.4%) 3 (1.4%) 1.000
Malignancy 2 (0.9%) 2 (0.9%) 1.000
Percentages were calculated based on the number of patients with valid data.
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The ancillary study included 738 patients among whom 228
fulfilled the main study inclusion criteria (ie, with active auto-
antibody positive disease, on medication for SLE). Among the
patients with active disease, 39.7% had severe and 60.3% non-
severe disease. Data from this ancillary study were used to esti-
mate the mean annual adjusted direct cost per patient of €3483,
which was 5.6% lower than the unadjusted cost. The adjusted
costs in the five countries were as follows: €2549 (Italy), €3067
(Germany), €3651 (UK), €4003 (France) and €4156 (Spain).
Healthcare resource use and associated mean annual direct
costs
Table 3 reports the costs of medical resources used by the
patients in the study.
Medications (€1880), hospitalisations (€981), investigative
tests (€472) and specialist visits (€359) represented 50.9%,
26.6%, 12.8% and 9.7%, respectively, of the estimated annual
total medical cost.
Medications
Over the study period, 92.7% of patients received corticoster-
oids, 75.6% antimalarials, 72.6% immunosuppressants, 24.1%
NSAIDs, 10.3% biologics and 60.4% anti-osteoporosis drugs
(see online supplementary table S4). Severe patients were more
frequently prescribed corticosteroids (97.6% vs 87.9%,
p<0.001), immunosuppressants (88.7% vs 56.7%, p<0.001)
including mycophenolate mofetil (59.9% vs 24.6%), and biolo-
gics (15.1% vs 5.6%, p=0.001).
The mean annual cost of medications for severe patients was
€2518, twice as high as for non-severe patients (€1251,
p<0.001). Medications were the main cost driver, representing
53.0% and 47.2% of the total cost of care for severe and non-
severe patients, respectively (table 3).
The costs of immunosuppressants and biologics were 2.9 and
2.7 times higher in severe compared to non-severe patients,
respectively (p<0.001 each). The mean annual cost of immuno-
suppressants and biologics represented 28.8% and 6.8% of the
total cost, respectively.
Among the five countries, the mean annual cost of treatments
ranged from €1436 (Spain) to €2542 (France), and represented
from 29.7% (Spain) to 68.1% (Germany) of the total medical
cost (figure 2).
Hospitalisations
During the study period, 43.1% of patients were admitted to
hospital at least once on an inpatient basis and 22.5% on a day
basis. Inpatient admissions (54.2% vs 32.1%, p<0.001) and day
hospitalisations (26.9% vs 18.1%, p=0.030) were higher for
severe patients. Inpatient admissions to intensive care and
rehabilitation units occurred in seven and 11 cases of severe and
non-severe disease, respectively. While hospitalisations
accounted for the same relative percentage (26–27%) of the
total direct costs for severe and non-severe patients, the absolute
cost for severe patients (€1247) was almost twice that of non-
severe patients (€718) (table 3). The mean cost of hospitalisa-
tions for severe patients was almost twice that of non-severe
patients (p<0.001).
Specialist visits
Over the study period, 70.7% of patients consulted a rheuma-
tologist (the primary SLE care management physician in Italy,
Germany and the UK). One third of patients consulted an oph-
thalmologist (34.9%) or an internist (37.7%). Other specialists,
such as nephrologists (14.8%) and dermatologists (13.6%), were
consulted by less than 15% of the patients. Only nephrologists
were 3.2 times more frequently consulted by severe patients
(22.6% vs 7.0%, p<0.001). The mean cost of specialist visits
was similar in the two groups of patients.
Laboratory tests
Over the study period, all patients had at least one laboratory
test. Biopsies were conducted in 18.3% of patients, more fre-
quently in severe than in non-severe patients (27.8% vs 8.8%,
p<0.001). Imaging tests were conducted in 65.8% of patients,
more frequently in severe than in non-severe patients (72.6% vs
59.1%, p<0.01).
The mean annual costs of laboratory tests, biopsies and
imaging tests were higher in severe patients than in non-severe
patients (p<0.001 each), representing 7.7%, 2.0% and 3.2% of
the total cost, respectively (table 3).
Predictors of costs
The univariate regression models tested and identified the vari-
ables used in multivariate models (see online supplementary
table S5). The multivariate regression models identified cost pre-
dictors on the study sample (table 4).
The occurrence of flares during the study period also resulted
in an average increment in the annual cost of 35.0% (+€399,
p=0.03), as compared to the cost of patients with no flares. The
strongest predictor of total costs was the annual number of
severe flares, with each severe flare resulting in a 97.4%
(+€1002, p<0.0001) increase in the annual cost of SLE. Other
important predictors of costs included major organ involvement,
resulting in incremental cost increases of 25.9–52.2% when the
following systems were involved: cardiovascular/respiratory (+
€596), renal (+€511), neurological (+€495) and haematological
Figure 2 Cost of each category of
health resource use (in €), globally and
in the five countries.
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(+€281). There were no significant differences related to the
specific countries where patients were treated.
DISCUSSION
The LUCIE study provides data on the healthcare resource utilisa-
tion and the direct medical costs of SLE management in Germany,
the UK, France, Italy and Spain. It included patients with active
disease and focused on the effect of disease severity, organ involve-
ment and treatments on the direct medical costs of SLE.
To our knowledge, this is the first time such data have been
available for France, Italy and Spain. Moreover, the study
provides an update on the cost of SLE care in Germany and
the UK.11 17 22
The demographic characteristics of patients were similar to
those reported in other European and international
studies.10 11 15 17 23 24 The mean direct annual costs, assessed in
the five countries and overall (€3483), were consistent with
those published in the two other European studies, which
ranged from €342117 to €363611 (€2009). However, it is diffi-
cult to compare the direct annual costs of SLE obtained in this
study with those in previous European studies as they were con-
ducted more than 10 years ago, before the widespread use of
biologics,11 17 and one study was conducted from a societal per-
spective.11 It is even more difficult to compare the costs
reported in North American studies with those in Western
European studies as the costs of SLE reported in the USA are
2.8 to four times higher (range: €9834–14 873 in €2009
[23, 24]). Differences can be attributed to variation in disease
severity profiles, study designs, healthcare systems, cost and rela-
tive prices.
Cost drivers and predictors identified in the literature were:
younger patients,9 17 high disease activity at onset9 10 or over
the disease course,10 17 flares, particularly major organ flares,10
greater disease damage,9 16 and disease severity including the
type of organ involvement, especially active glomeruloneph-
ritis12 16 23 25–27 and neuropsychiatric involvement.28
This study shows that high disease severity and disease flares
increase the total medical cost.
The highest costs of SLE management are related to major
organ involvement (renal, neurological, cardiovascular and/or
respiratory domains) and consequently to severe disease.
Medications, especially immunosuppressants and biologics, were
more often prescribed in severe patients and to treat severe flares.
They represented approximately half of the costs and were iden-
tified as the main cost drivers, especially for immunosuppressants
and biologics. The costs of medications were twice as high as
those described in previous European studies, where they repre-
sented 17.3% (€592)17 and 26.6% (€967)11 of the total cost.
However, these European studies were conducted more than
10 years ago and did not use biologics, which were used in our
study and explained 6.8% of the annual total cost. In the last few
years, SLE recommendations and care management have
changed,3–6 especially with regards to the use of biologics.
The costs of SLE medications had the widest range (€247–
2527; €2009) in the US studies, representing from 4.0%28 to
25.7% of the total cost.23 24
In addition, one major difference between our study and the
others is probably the high disease activity of our patients,
observed especially in severe patients, who required high doses
of medications and/or immunosuppressive treatments. Notably,
the use of mycophenolate mofetil, the most expensive immuno-
suppressant, has increased in the last few years.12
The highest costs are related to the number of severe flares,
and thus to disease activity. Severe flares, which required hospi-
talisation in 25% of cases, were identified as the major cost pre-
dictors. Actually, the annual mean number of flares was similar
to that reported in two recent studies in patients who experi-
enced flares.10 28 As in our study, the direct cost of these
patients with severe (renal/neuropsychiatric) flares was higher
compared to those with no flares.10 28
Table 3 Description of annual direct medical cost of active SLE









p ValueMean %* Mean %*
Total annual cost (€) 4748 2650 <0.001
Laboratory tests (€)
Any test 330 6.9 236 8.9 <0.001
Immunological tests 119 2.5 93 3.5 <0.001
Blood chemistry tests 138 2.9 99 3.8 <0.001
Haematology tests 50 1.1 31 1.2 0.035
Other biological test 22 0.5 13 0.47 <0.001
Biopsies and imaging tests (€)
Any test 257 5.4 124 4.7 <0.001
Biopsies 123 2.6 25 0.95 <0.001
Imaging test 134 2.8 99 3.7 0.004
Medication (€)
Any medication 2518 53.0 1251 47.2 <0.001
NSAIDS 6.6 0.1 10.3 0.39 0.071
Corticosteroids 131 2.8 65 2.4 <0.001
Antimalarials 68 1.4 76 2.9 0.389
Immunosuppressants 1586 33.4 549 20.7 <0.001
Biologics 367 7.7 137 5.2 <0.001
Anti-osteoporosis drugs 269 5.7 246 9.3 0.353
Other treatments 90 1.9 168 6.3 0.615
Specialist visits (€)
Any visits 396 8.4 322 12.1 0.069
Dermatologist 6.4 0.14 9.4 0.35 0.506
Ophthalmologist 10.3 0.22 14.7 0.56 0.224
Rheumatologist 187 4.0 180 6.8 0.712
Pulmonologist 3.6 0.07 5.1 0.19 0.711
Cardiologist 4.5 0.09 6.0 0.23 0.959
Neurologist 11 0.24 5.2 0.20 0.136
Nephrologist 31 0.66 9.8 0.37 <0.001
Psychiatrist 3.8 0.08 1.4 0.05 0.625
Internist 100 2.1 63 2.8 0.172
Surgical visit(s) 7.5 0.16 6.9 0.26 0.400
Other visits 31 0.65 20 0.76 0.921
Hospitalisations 1247 26.3 718 27.1 <0.001
Outpatient visits (€) (only for UK)
Any visit 16.6 0.35 7.0 0.26 0.115
Without physician 10.1 0.21 5.3 0.20 0.314
With physician 6.5 0.14 1.7 0.06 0.077
Day hospitalisation/day surgery (€) 53 1.1 40 1.5 0.057
Emergency room visits (€) 10 0.21 14.0 0.53 0.390
Inpatient stays (€) 1160 24.4 645 24.3 <0.001
Rehabilitation stays (€) 8.1 0.17 12.1 0.46 0.785
*Percentage calculated as mean cost of each health resource with respect to global
costs in each severity group and for overall study sample.
Percentages were calculated using the number of valid data.
SLE, systemic lupus erythematosus.
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The LUCIE study has a number of limitations. A 50 : 50 div-
ision between severe and non-severe patients was chosen in
order to have enough power to analyse these two subgroups.
The ancillary study results demonstrate that the adjusted mean
cost is only 5.6% lower than the unadjusted cost. Patients’
disease severity and activity profile were assessed only at base-
line. Consequently, the potential for disease progression during
the 2-year follow-up period was not measured. In addition, the
2-year study duration did not allow damage accrual and the
long term effects of the disease and the medications to be cap-
tured. Due to the retrospective nature of the study, the evalu-
ation of direct medical costs may be underestimated because it
was not possible to capture all components of the direct medical
costs (eg, non-specialist visits and treatments associated with
SLE comorbidities, antibiotics). Finally, as there is no generally
accepted definition of a lupus flare, it was necessary to define
specific criteria to identify the beginning of a flare. However,
the mean number of flares observed was in line with previously
published studies. Nevertheless, information regarding flare dur-
ation and organ flaring was not collected.
In conclusion, the LUCIE study provides a reliable insight into
SLE clinical profiles and costs of care management in Europe. It
showed that the costs are related to disease severity and disease
flares, and suggests focusing on preventing flare occurrence and
limiting disease progression in order to reduce related costs. The
cost of treating SLE patients observed in our study and others is
lower than that of other chronic diseases, for example, the cost
of multiple sclerosis is 2.5 to 5-times higher to that of SLE;29
however, it appears to be high if we consider the cost/year over a
patient’s lifetime, especially for severe patients.
SLE care management has improved during the last few years,
resulting in a significant increase in patient survival.30 But even
if treatment results in long periods of disease remission, SLE
remains alternatively active in a high percentage of cases over
time.31 Thus other new therapies are needed, to stop disease
activity, limit the constant disease evolution and potentially
delay the progression of disease.
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